New investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing significant effects in managing excess mass and related second-type disease. Initial evidence suggest a novel process https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/